Invivyd Reports Positive Phase 3 LIBERTY Data for VYD2311
NEW HAVEN, Conn. — September 29, 202 Invivyd announced topline results from the Phase 3 LIBERTY study evaluating VYD2311,...
infectious disease
Advertisement
AN2 Therapeutics Extends GSK Tuberculosis Research Collaboration
MENLO PARK, Calif. — September 28, 2026 AN2 Therapeutics, Inc. announced that the Gates Foundation has extended funding supporting...
ClorDiSys Advances Cold-Chain Sterilization for Pharma
Branchburg, New Jersey, U.S., September 22, 2026 ClorDiSys Solutions Inc. has announced the publication of a peer-reviewed study in...
Tampa General Adopts Host-Response Technology for Sepsis
Tampa, Florida, U.S., September 22, 2026 Tampa General Hospital has become the first academic health system in the Southeast...
Insmed Wins FDA Priority Review for ARIKAYCE sNDA
Bridgewater, New Jersey, U.S., September 21, 2026 Insmed has announced that the U.S. Food and Drug Administration (FDA) has...
Advertisements
Kamada Confirms KedRAB Supply Amid Rising U.S. Rabies Demand
REHOVOT, Israel and HOBOKEN, N.J. — September 17, 2026 Kamada Ltd. confirmed that it has sufficient KedRAB® inventory and...
Sunshine Biopharma Advances PLpro Inhibitor Toward IND
FORT LAUDERDALE, Fla. — September 16, 2026 Sunshine Biopharma Inc. announced that it has advanced its lead Coronavirus drug...
Cocrystal Pharma Advances CDI-988 in Norovirus Challenge Study
MIAMI, Fla. and BOTHELL, Wash. — September 9, 2026 Cocrystal Pharma, Inc. announced that the last subject has been...
Shionogi Expands Fetroja Role in U.S. Drug-Resistance Preparedness
Osaka, Japan – August 28, 2026 Shionogi & Co., Ltd. announced that the Biomedical Advanced Research and Development Authority...
Pfizer and BioNTech Win FDA Approval for XFG COVID-19 Vaccine
NEW YORK, NY and MAINZ, Germany – August 27, 2026 Pfizer Inc. and BioNTech SE announced that the U.S....
Advertisement
